세계의 오피오이드 사용 장애(OUD) 시장 규모, 점유율, 산업 동향 분석 보고서 : 약품 등급별(부프레노르핀, 메타돈, 나르트렉손), 투여 경로별, 유통 채널별, 지역별 전망 및 예측(2023-2030년)

The Global Opioid Use Disorder (OUD) Market size is expected to reach $6.4 billion by 2030, rising at a market growth of 9.9% CAGR during the forecast period.

Asia Pacific region healthcare sector is anticipated to rise due to the general public's increased knowledge of opioid disorders and the region's rising healthcare spending. Consequently, APAC registered $706.9 million revenue in the market in 2022. Growing elderly populations, increased public knowledge of healthcare services, and an increase in chronic diseases are all factors responsible for the growth. On the other hand, the Methadone Maintenance Treatment Program, a multifaceted therapy method that aims to reduce the health and social problem caused by drug diseases, was successfully implemented by the China' government to address the severe drug problem in China. Some of the factors impacting the market are expanding the use of buprenorphine patches in therapy, growing focus of non-governmental & governmental institutions for raising awareness, and OUD Drugs' negative effects.

The increasing use of buprenorphine patches as a successful treatment for opioid use disorder is one of the forthcoming trends in the market. One of the most cutting-edge methods for treating opioid use disorder is the use of buprenorphine patches. Transdermal patches are a more comfortable drug delivery method that successfully lowers pain and can be self-administered by the patient than traditional treatment techniques such as injections. A significant aspect that is fueling the market's growth is the increasing involvement of governmental and non-governmental groups in raising awareness about opioid overdose and its dangers. A number of groups have expanded their efforts to address the issue as a result of the sharp rise in the number of opioid addicts.

However, these medications frequently cause muscle aches, nausea, vomiting, diarrhea, constipation, respiratory problems, bone/joint pain, bladder pain, and abdominal cramping. In addition, when a drug reaction is strong, the patient may also experience depression and other psychological issues. Clinical concerns about physical dependence and addiction may hinder appropriate prescribing, resulting in insufficient pain management. These negative effects may limit the expansion of the market. The COVID-19 pandemic affected pharmaceutical firms in both favorable and negative manner, depending on demand. Certain pharmaceutical products saw decreased demand as fewer individuals risked going to healthcare facilities like hospitals and clinics. The respective governments implemented strict national lockdowns to stop the spread of virus from spreading. As a result of COVID-19-related disruptions, sales continued to decline sharply. As a result, during the pandemic, there was a declining tendency in the worldwide economy.

Drug Class Outlook

Based on drug, the market is classified into buprenorphine, methadone, and naltrexone. In 2022, the buprenorphine segment dominated the market with the maximum revenue share. The market witnessed a rise in demand for buprenorphine patch treatments. These patches are regarded as an efficient therapy for treating opioid use disorder. Transdermal patches have several common and self-administered benefits, including improving the mechanism of drug delivery and reducing pain. These transdermal patches can also be an alternative for people who need 24/7 opioid medication for OUD. SUBLOCADE, SUBOXONE, and ZUBSOLV are some crucial buprenorphine medications.

Route of Administration Outlook

On the basis of route of administration, the market is fragmented into oral, and parenteral. The parenteral segment held the highest revenue share in the market in 2022. The parenteral method can be used to supplement calories and deliver medications quickly. Parenteral administration allows for the drug to reach the bloodstream quickly, resulting in a rapid onset of action. This is particularly important in managing opioid withdrawal symptoms and providing immediate relief to individuals with OUD. The parenteral route can help minimize the risk of drug diversion and misuse since the medication is administered by healthcare professionals. These benefits of parenteral administration are predicted to support the market growth in this segment.

Distribution Channel Outlook

By distribution channel, the market is categorized into hospital pharmacies, retail pharmacies & stores, and online pharmacies. The online pharmacies segment projected a prominent revenue share in the market in 2022. This is attributed to the increasing usage of e-prescriptions at hospitals along with other healthcare facilities as well as the growth in internet users, increased accessibility to online services, and other factors. The growth of online pharmacy is also fueled by the expansion of teleconsultation and diagnostic support. Nowadays, e-prescriptions that can be used to buy medications from online pharmacies can be created through remote consultation.

Regional Outlook

Region wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region led the market by generating highest revenue share in the market. One of the main factors influencing North America's most significant revenue share is the opioid epidemic in the United States and Canada. Chronic diseases, which are becoming increasingly prevalent, are the primary drivers of the rising usage of opioids for the management of pain. This is predicted to rise the prevalence of OUD, thereby offering growth prospects in the region.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Indivior PLC (Reckitt Benckiser Group plc), Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.), Orexo AB (Orexo US, Inc.), Alkermes PLC, Titan Pharmaceuticals, Inc., Camurus AB, AstraZeneca PLC, Hikma Pharmaceuticals PLC, Mallinckrodt PLC, and Viatris, Inc.

Strategies Deployed in Opioid Use Disorder (OUD) Market

May-2023: Indivior PLC received approval from the U.S. Food and Drug Administration for OPVEE (nalmefene) nasal spray for the treatment of opioid overdose induced by natural or synthetic opioids. OPVEE contains nalmefene, an opioid receptor that delivers fast onset and long-duration reversal of opioid-induced respiratory depression.

May-2023: Camurus received approval from the US Food and Drug Administration (FDA) for its Brixadi (buprenorphine) extended-release injection for subcutaneous (SC) use, to treat moderate to severe opioid use disorder. The Brixadi would be used as a part of a complete treatment plan that includes counseling and psychosocial support.

Mar-2023: Indivior PLC took over Opiant Pharmaceuticals, Inc., a pharmaceutical company that develops treatments for drug overdose and addictions. The acquisition strengthens the addiction treatment and science portfolio of the company by adding Opiant's late-stage assets, notably OPNT003, an investigational opioid overdose treatment.

Jan-2023: Hikma Pharmaceuticals PLC revealed Naloxone Hydrochloride Injection, USP, 2mg/2mL, in the prefilled syringe (PFS) form. The drug is used to treat known or suspected opioid overdose. The launch expands the portfolio of addiction therapy treatments of the company.

Sep-2022: Orexo AB formed a partnership with Trinity Health, a comprehensive healthcare system. With this partnership, Trinity Health would offer Orexo's evidence-based digital therapies vorvida® and deprexis® to help patients manage depression and excessive drinking and expand patient access to digital therapeutics.

Jul-2022: Titan Pharmaceuticals, Inc. got approval for its Investigational New Drug ("IND") application from U.S. Food and Drug Administration ("FDA"), for the Phase 1 study of its subdermal formulation of nalmefene, an opioid antagonist which is to be used in the prevention of relapse following opioid detoxification in adults with Opioid Use Disorder ("OUD").

Jul-2021: AstraZeneca took over Alexion Pharmaceuticals, a global biopharmaceutical company. Through this acquisition, the company would be able to enter into medicines for rare diseases and the beginning of a new chapter. Further, the acquisition improved AstraZeneca's scientific presence in immunology and, through Alexion's new complement-biology platform and robust pipeline, would continue to pioneer the discovery & development of medicines for patients with rare diseases.

Jun-2021: U.S. Food and Drug Administration (FDA) has approved LYBALVI (olanzapine and samidorphan), an oral atypical antipsychotic of Alkermes plc, for the treatment of schizophrenia and bipolar I disorder.

Aug-2019: Orexo AB signed an agreement with GAIA AG, a health company that specializes in the development of eHealth and mHealth interventions. The agreement enables the company to have global commercial rights to the product. Both companies would leverage proven effective treatments and technology to bring new digital therapeutics products.

Jul-2019: Camurus AB signed a license agreement with Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, for the use of Camurus's proprietary FluidCrystal® (FC) technology in the development, manufacturing, and commercializing formulation of zilucoplan. The agreement enables the company to develop new promising product candidates based on our unique FluidCrystal® technology.

Scope of the Study

Market Segments covered in the Report:

By Drug Class

• Buprenorphine
• Methadone
• Naltrexone

By Route of Administration

• Parenteral
• Oral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies & Stores
• Online Pharmacies

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled

• Indivior PLC (Reckitt Benckiser Group plc)
• Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.)
• Orexo AB (Orexo US, Inc.)
• Alkermes PLC
• Titan Pharmaceuticals, Inc.
• Camurus AB
• AstraZeneca PLC
• Hikma Pharmaceuticals PLC
• Mallinckrodt PLC
• Viatris, Inc.

Unique Offerings from KBV Research

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

• 1.1 Market Definition
• 1.2 Objectives
• 1.3 Market Scope
• 1.4 Segmentation
  • 1.4.1 Global Opioid Use Disorder (OUD) Market, by Drug Class
  • 1.4.2 Global Opioid Use Disorder (OUD) Market, by Route of Administration
  • 1.4.3 Global Opioid Use Disorder (OUD) Market, by Distribution Channel
  • 1.4.4 Global Opioid Use Disorder (OUD) Market, by Geography
• 1.5 Methodology for the research

Chapter 2. Market Overview

• 2.1 Introduction
  • 2.1.1 Overview
    • 2.1.1.1 Market Composition and Scenario
• 2.2 Key Factors Impacting the Market
  • 2.2.1 Market Drivers
  • 2.2.2 Market Restraints

Chapter 3. Strategies Deployed in Opioid Use Disorder (OUD) Market

Chapter 4. Global Opioid Use Disorder (OUD) Market by Drug Class

• 4.1 Global Buprenorphine Market by Region
• 4.2 Global Methadone Market by Region
• 4.3 Global Naltrexone Market by Region

Chapter 5. Global Opioid Use Disorder (OUD) Market by Route of Administration

• 5.1 Global Parenteral Market by Region
• 5.2 Global Oral Market by Region

Chapter 6. Global Opioid Use Disorder (OUD) Market by Distribution Channel

• 6.1 Global Hospital Pharmacies Market by Region
• 6.2 Global Retail Pharmacies & Stores Market by Region
• 6.3 Global Online Pharmacies Market by Region

Chapter 7. Global Opioid Use Disorder (OUD) Market by Region

• 7.1 North America Opioid Use Disorder (OUD) Market
  • 7.1.1 North America Opioid Use Disorder (OUD) Market by Drug Class
    • 7.1.1.1 North America Buprenorphine Market by Country
    • 7.1.1.2 North America Methadone Market by Country
    • 7.1.1.3 North America Naltrexone Market by Country
  • 7.1.2 North America Opioid Use Disorder (OUD) Market by Route of Administration
    • 7.1.2.1 North America Parenteral Market by Country
    • 7.1.2.2 North America Oral Market by Country
  • 7.1.3 North America Opioid Use Disorder (OUD) Market by Distribution Channel
    • 7.1.3.1 North America Hospital Pharmacies Market by Country
    • 7.1.3.2 North America Retail Pharmacies & Stores Market by Country
    • 7.1.3.3 North America Online Pharmacies Market by Country
  • 7.1.4 North America Opioid Use Disorder (OUD) Market by Country
    • 7.1.4.1 US Opioid Use Disorder (OUD) Market
      • 7.1.4.1.1 US Opioid Use Disorder (OUD) Market by Drug Class
      • 7.1.4.1.2 US Opioid Use Disorder (OUD) Market by Route of Administration
      • 7.1.4.1.3 US Opioid Use Disorder (OUD) Market by Distribution Channel
    • 7.1.4.2 Canada Opioid Use Disorder (OUD) Market
      • 7.1.4.2.1 Canada Opioid Use Disorder (OUD) Market by Drug Class
      • 7.1.4.2.2 Canada Opioid Use Disorder (OUD) Market by Route of Administration
      • 7.1.4.2.3 Canada Opioid Use Disorder (OUD) Market by Distribution Channel
    • 7.1.4.3 Mexico Opioid Use Disorder (OUD) Market
      • 7.1.4.3.1 Mexico Opioid Use Disorder (OUD) Market by Drug Class
      • 7.1.4.3.2 Mexico Opioid Use Disorder (OUD) Market by Route of Administration
      • 7.1.4.3.3 Mexico Opioid Use Disorder (OUD) Market by Distribution Channel
    • 7.1.4.4 Rest of North America Opioid Use Disorder (OUD) Market
      • 7.1.4.4.1 Rest of North America Opioid Use Disorder (OUD) Market by Drug Class
      • 7.1.4.4.2 Rest of North America Opioid Use Disorder (OUD) Market by Route of Administration
      • 7.1.4.4.3 Rest of North America Opioid Use Disorder (OUD) Market by Distribution Channel
• 7.2 Europe Opioid Use Disorder (OUD) Market
  • 7.2.1 Europe Opioid Use Disorder (OUD) Market by Drug Class
    • 7.2.1.1 Europe Buprenorphine Market by Country
    • 7.2.1.2 Europe Methadone Market by Country
    • 7.2.1.3 Europe Naltrexone Market by Country
  • 7.2.2 Europe Opioid Use Disorder (OUD) Market by Route of Administration
    • 7.2.2.1 Europe Parenteral Market by Country
    • 7.2.2.2 Europe Oral Market by Country
  • 7.2.3 Europe Opioid Use Disorder (OUD) Market by Distribution Channel
    • 7.2.3.1 Europe Hospital Pharmacies Market by Country
    • 7.2.3.2 Europe Retail Pharmacies & Stores Market by Country
    • 7.2.3.3 Europe Online Pharmacies Market by Country
  • 7.2.4 Europe Opioid Use Disorder (OUD) Market by Country
    • 7.2.4.1 Germany Opioid Use Disorder (OUD) Market
      • 7.2.4.1.1 Germany Opioid Use Disorder (OUD) Market by Drug Class
      • 7.2.4.1.2 Germany Opioid Use Disorder (OUD) Market by Route of Administration
      • 7.2.4.1.3 Germany Opioid Use Disorder (OUD) Market by Distribution Channel
    • 7.2.4.2 UK Opioid Use Disorder (OUD) Market
      • 7.2.4.2.1 UK Opioid Use Disorder (OUD) Market by Drug Class
      • 7.2.4.2.2 UK Opioid Use Disorder (OUD) Market by Route of Administration
      • 7.2.4.2.3 UK Opioid Use Disorder (OUD) Market by Distribution Channel
    • 7.2.4.3 France Opioid Use Disorder (OUD) Market
      • 7.2.4.3.1 France Opioid Use Disorder (OUD) Market by Drug Class
      • 7.2.4.3.2 France Opioid Use Disorder (OUD) Market by Route of Administration
      • 7.2.4.3.3 France Opioid Use Disorder (OUD) Market by Distribution Channel
    • 7.2.4.4 Russia Opioid Use Disorder (OUD) Market
      • 7.2.4.4.1 Russia Opioid Use Disorder (OUD) Market by Drug Class
      • 7.2.4.4.2 Russia Opioid Use Disorder (OUD) Market by Route of Administration
      • 7.2.4.4.3 Russia Opioid Use Disorder (OUD) Market by Distribution Channel
    • 7.2.4.5 Spain Opioid Use Disorder (OUD) Market
      • 7.2.4.5.1 Spain Opioid Use Disorder (OUD) Market by Drug Class
      • 7.2.4.5.2 Spain Opioid Use Disorder (OUD) Market by Route of Administration
      • 7.2.4.5.3 Spain Opioid Use Disorder (OUD) Market by Distribution Channel
    • 7.2.4.6 Italy Opioid Use Disorder (OUD) Market
      • 7.2.4.6.1 Italy Opioid Use Disorder (OUD) Market by Drug Class
      • 7.2.4.6.2 Italy Opioid Use Disorder (OUD) Market by Route of Administration
      • 7.2.4.6.3 Italy Opioid Use Disorder (OUD) Market by Distribution Channel
    • 7.2.4.7 Rest of Europe Opioid Use Disorder (OUD) Market
      • 7.2.4.7.1 Rest of Europe Opioid Use Disorder (OUD) Market by Drug Class
      • 7.2.4.7.2 Rest of Europe Opioid Use Disorder (OUD) Market by Route of Administration
      • 7.2.4.7.3 Rest of Europe Opioid Use Disorder (OUD) Market by Distribution Channel
• 7.3 Asia Pacific Opioid Use Disorder (OUD) Market
  • 7.3.1 Asia Pacific Opioid Use Disorder (OUD) Market by Drug Class
    • 7.3.1.1 Asia Pacific Buprenorphine Market by Country
    • 7.3.1.2 Asia Pacific Methadone Market by Country
    • 7.3.1.3 Asia Pacific Naltrexone Market by Country
  • 7.3.2 Asia Pacific Opioid Use Disorder (OUD) Market by Route of Administration
    • 7.3.2.1 Asia Pacific Parenteral Market by Country
    • 7.3.2.2 Asia Pacific Oral Market by Country
  • 7.3.3 Asia Pacific Opioid Use Disorder (OUD) Market by Distribution Channel
    • 7.3.3.1 Asia Pacific Hospital Pharmacies Market by Country
    • 7.3.3.2 Asia Pacific Retail Pharmacies & Stores Market by Country
    • 7.3.3.3 Asia Pacific Online Pharmacies Market by Country
  • 7.3.4 Asia Pacific Opioid Use Disorder (OUD) Market by Country
    • 7.3.4.1 China Opioid Use Disorder (OUD) Market
      • 7.3.4.1.1 China Opioid Use Disorder (OUD) Market by Drug Class
      • 7.3.4.1.2 China Opioid Use Disorder (OUD) Market by Route of Administration
      • 7.3.4.1.3 China Opioid Use Disorder (OUD) Market by Distribution Channel
    • 7.3.4.2 Japan Opioid Use Disorder (OUD) Market
      • 7.3.4.2.1 Japan Opioid Use Disorder (OUD) Market by Drug Class
      • 7.3.4.2.2 Japan Opioid Use Disorder (OUD) Market by Route of Administration
      • 7.3.4.2.3 Japan Opioid Use Disorder (OUD) Market by Distribution Channel
    • 7.3.4.3 India Opioid Use Disorder (OUD) Market
      • 7.3.4.3.1 India Opioid Use Disorder (OUD) Market by Drug Class
      • 7.3.4.3.2 India Opioid Use Disorder (OUD) Market by Route of Administration
      • 7.3.4.3.3 India Opioid Use Disorder (OUD) Market by Distribution Channel
    • 7.3.4.4 South Korea Opioid Use Disorder (OUD) Market
      • 7.3.4.4.1 South Korea Opioid Use Disorder (OUD) Market by Drug Class
      • 7.3.4.4.2 South Korea Opioid Use Disorder (OUD) Market by Route of Administration
      • 7.3.4.4.3 South Korea Opioid Use Disorder (OUD) Market by Distribution Channel
    • 7.3.4.5 Singapore Opioid Use Disorder (OUD) Market
      • 7.3.4.5.1 Singapore Opioid Use Disorder (OUD) Market by Drug Class
      • 7.3.4.5.2 Singapore Opioid Use Disorder (OUD) Market by Route of Administration
      • 7.3.4.5.3 Singapore Opioid Use Disorder (OUD) Market by Distribution Channel
    • 7.3.4.6 Malaysia Opioid Use Disorder (OUD) Market
      • 7.3.4.6.1 Malaysia Opioid Use Disorder (OUD) Market by Drug Class
      • 7.3.4.6.2 Malaysia Opioid Use Disorder (OUD) Market by Route of Administration
      • 7.3.4.6.3 Malaysia Opioid Use Disorder (OUD) Market by Distribution Channel
    • 7.3.4.7 Rest of Asia Pacific Opioid Use Disorder (OUD) Market
      • 7.3.4.7.1 Rest of Asia Pacific Opioid Use Disorder (OUD) Market by Drug Class
      • 7.3.4.7.2 Rest of Asia Pacific Opioid Use Disorder (OUD) Market by Route of Administration
      • 7.3.4.7.3 Rest of Asia Pacific Opioid Use Disorder (OUD) Market by Distribution Channel
• 7.4 LAMEA Opioid Use Disorder (OUD) Market
  • 7.4.1 LAMEA Opioid Use Disorder (OUD) Market by Drug Class
    • 7.4.1.1 LAMEA Buprenorphine Market by Country
    • 7.4.1.2 LAMEA Methadone Market by Country
    • 7.4.1.3 LAMEA Naltrexone Market by Country
  • 7.4.2 LAMEA Opioid Use Disorder (OUD) Market by Route of Administration
    • 7.4.2.1 LAMEA Parenteral Market by Country
    • 7.4.2.2 LAMEA Oral Market by Country
  • 7.4.3 LAMEA Opioid Use Disorder (OUD) Market by Distribution Channel
    • 7.4.3.1 LAMEA Hospital Pharmacies Market by Country
    • 7.4.3.2 LAMEA Retail Pharmacies & Stores Market by Country
    • 7.4.3.3 LAMEA Online Pharmacies Market by Country
  • 7.4.4 LAMEA Opioid Use Disorder (OUD) Market by Country
    • 7.4.4.1 Brazil Opioid Use Disorder (OUD) Market
      • 7.4.4.1.1 Brazil Opioid Use Disorder (OUD) Market by Drug Class
      • 7.4.4.1.2 Brazil Opioid Use Disorder (OUD) Market by Route of Administration
      • 7.4.4.1.3 Brazil Opioid Use Disorder (OUD) Market by Distribution Channel
    • 7.4.4.2 Argentina Opioid Use Disorder (OUD) Market
      • 7.4.4.2.1 Argentina Opioid Use Disorder (OUD) Market by Drug Class
      • 7.4.4.2.2 Argentina Opioid Use Disorder (OUD) Market by Route of Administration
      • 7.4.4.2.3 Argentina Opioid Use Disorder (OUD) Market by Distribution Channel
    • 7.4.4.3 UAE Opioid Use Disorder (OUD) Market
      • 7.4.4.3.1 UAE Opioid Use Disorder (OUD) Market by Drug Class
      • 7.4.4.3.2 UAE Opioid Use Disorder (OUD) Market by Route of Administration
      • 7.4.4.3.3 UAE Opioid Use Disorder (OUD) Market by Distribution Channel
    • 7.4.4.4 Saudi Arabia Opioid Use Disorder (OUD) Market
      • 7.4.4.4.1 Saudi Arabia Opioid Use Disorder (OUD) Market by Drug Class
      • 7.4.4.4.2 Saudi Arabia Opioid Use Disorder (OUD) Market by Route of Administration
      • 7.4.4.4.3 Saudi Arabia Opioid Use Disorder (OUD) Market by Distribution Channel
    • 7.4.4.5 South Africa Opioid Use Disorder (OUD) Market
      • 7.4.4.5.1 South Africa Opioid Use Disorder (OUD) Market by Drug Class
      • 7.4.4.5.2 South Africa Opioid Use Disorder (OUD) Market by Route of Administration
      • 7.4.4.5.3 South Africa Opioid Use Disorder (OUD) Market by Distribution Channel
    • 7.4.4.6 Nigeria Opioid Use Disorder (OUD) Market
      • 7.4.4.6.1 Nigeria Opioid Use Disorder (OUD) Market by Drug Class
      • 7.4.4.6.2 Nigeria Opioid Use Disorder (OUD) Market by Route of Administration
      • 7.4.4.6.3 Nigeria Opioid Use Disorder (OUD) Market by Distribution Channel
    • 7.4.4.7 Rest of LAMEA Opioid Use Disorder (OUD) Market
      • 7.4.4.7.1 Rest of LAMEA Opioid Use Disorder (OUD) Market by Drug Class
      • 7.4.4.7.2 Rest of LAMEA Opioid Use Disorder (OUD) Market by Route of Administration
      • 7.4.4.7.3 Rest of LAMEA Opioid Use Disorder (OUD) Market by Distribution Channel

Chapter 8. Company Profiles

• 8.1 Indivior PLC (Reckitt Benckiser Group plc)
  • 8.1.1 Company Overview
  • 8.1.2 Financial Analysis
  • 8.1.3 Product and Regional Analysis
  • 8.1.4 Research & Development Expenses
  • 8.1.5 Recent strategies and developments:
    • 8.1.5.1 Partnerships, Collaborations, and Agreements:
    • 8.1.5.2 Acquisition and Mergers:
• 8.2 Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.)
  • 8.2.1 Company Overview
  • 8.2.2 Financial Analysis
  • 8.2.3 Research & Development Expenses
• 8.3 Orexo AB (Orexo US, Inc.)
  • 8.3.1 Company Overview
  • 8.3.2 Financial Analysis
  • 8.3.3 Segmental and Regional Analysis
  • 8.3.4 Research & Development Expenses
  • 8.3.5 Recent strategies and developments:
    • 8.3.5.1 Partnerships, Collaborations, and Agreements:
• 8.4 Alkermes PLC
  • 8.4.1 Company Overview
  • 8.4.2 Financial Analysis
  • 8.4.3 Regional Analysis
  • 8.4.4 Research & Development Expenses
  • 8.4.5 Recent strategies and developments:
    • 8.4.5.1 Trials and Approvals:
• 8.5 Titan Pharmaceuticals, Inc.
  • 8.5.1 Company Overview
  • 8.5.2 Financial Analysis
  • 8.5.3 Segmental and Regional Analysis
  • 8.5.4 Research & Development Expenses
  • 8.5.5 Recent strategies and developments:
    • 8.5.5.1 Trials and Approvals:
• 8.6 Camurus AB
  • 8.6.1 Company Overview
  • 8.6.2 Financial Analysis
  • 8.6.3 Segmental and Regional Analysis
  • 8.6.4 Research & Development Expenses
  • 8.6.5 Recent strategies and developments:
    • 8.6.5.1 Partnerships, Collaborations, and Agreements:
    • 8.6.5.2 Trials and Approvals:
• 8.7 AstraZeneca PLC
  • 8.7.1 Company Overview
  • 8.7.2 Financial Analysis
  • 8.7.3 Regional Analysis
  • 8.7.4 Research & Development Expenses
  • 8.7.5 Recent strategies and developments:
    • 8.7.5.1 Acquisition and Mergers:
• 8.8 Hikma Pharmaceuticals PLC
  • 8.8.1 Company Overview
  • 8.8.2 Financial Analysis
  • 8.8.3 Segmental and Regional Analysis
  • 8.8.4 Research & Development Expenses
  • 8.8.5 Recent strategies and developments:
    • 8.8.5.1 Product Launches and Product Expansions:
• 8.9 Mallinckrodt PLC
  • 8.9.1 Company Overview
  • 8.9.2 Financial Analysis
  • 8.9.3 Segmental and Regional Analysis
  • 8.9.4 Research & Development Expense
• 8.10. Viatris, Inc.
  • 8.10.1 Company Overview
  • 8.10.2 Financial Analysis
  • 8.10.3 Segmental Analysis
  • 8.10.4 Research & Development Expense